Trial Profile
The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 May 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Aug 2013 New trial record